New drug combo aims to help patients reduce dependency on standard ITP medications
NCT ID NCT07421167
Summary
This study is testing whether adding an investigational drug called ianalumab to a standard ITP medication (TPO-RA) is safe and tolerable for adults with primary immune thrombocytopenia. The main goal is to see if patients can handle the combination treatment and if it helps them eventually reduce or stop their standard TPO-RA medication. Researchers will also monitor if platelet counts improve and track side effects over about 15 months of follow-up.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.